Ebronucimab vs Lerodalcibep

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atherosclerotic Cardiovascular Disease

Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline

Ebronucimab

Marketed by Hubei Jumpcan Pharmaceutical and partners

Phase 3 in Atherosclerotic Cardiovascular Diseasemonoclonal antibody
Partial signal

NCT05255094 · Phase 3 · completed

The trial was randomized, quadruple-blind, placebo-controlled, and enrolled 464 participants, providing a strong experimental design. Its primary endpoint was a laboratory lipid measure rather than a hard clinical outcome. The registry record gives no statistical test for the primary comparison; the key result shown reports it from the cited source.

Reported efficacy

Percentage change from baseline of serum LDL-C level (At week 12): LDL-C percentage change from baseline to week 12 vs placebo: 450 mg Q4W -59.13 percentage points (95% CI -64.10 to -54.15, adjusted p<0.0001); 150 mg Q2W -60.43 percentage points (95% CI -65.45 to -55.416, adjusted p<0.0001). (met)

Result source: NCT05255094

Lerodalcibep · Lerochol

Marketed by LIB Therapeutics and partners

Phase 3 in Atherosclerotic Cardiovascular Diseasesmall protein (recombinant fusion protein)
Reliable signal

NCT04797104 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial in 478 patients that measured LDL-cholesterol lowering, the standard efficacy measure for this drug class. Lerodalcibep reduced LDL-C by more than half compared with placebo, a highly statistically significant result.

Next expected readout: July 2028 · NCT07102511 (registry estimate)

Reported efficacy

Change from baseline compared to placebo in LDL-C level (24 weeks): LDL-C at Week 24: placebo-adjusted reduction of 58.61% (P<.0001); co-primary endpoint, mean of Weeks 22 and 24: placebo-adjusted reduction of 65.0% (P<.0001) (met)

Result source: NCT04797104

Results for Atherosclerotic Cardiovascular Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointEbronucimabLerodalcibep
LDL-C, % change—Not posted · NCT05260411-53% vs -45.3%avs inclisiranwk 38.5714285714NCT05004675
1 other result
Non-HDL-C, % change—Not posted · NCT05260411—Not posted · NCT04790513
ApoB, % change—Not posted · NCT05260411—Not posted · NCT04790513
Lp(a), % change—Not posted · NCT05260411—Not posted · NCT04790513
3-point MACE (% with event)—Not posted · NCT05260411—Not posted · NCT04790513

LDL-C, % change

Ebronucimab
—Not posted · NCT05260411
Lerodalcibep
-53% vs -45.3%avs inclisiranwk 38.5714285714NCT05004675
1 other result

Non-HDL-C, % change

Ebronucimab
—Not posted · NCT05260411
Lerodalcibep
—Not posted · NCT04790513

ApoB, % change

Ebronucimab
—Not posted · NCT05260411
Lerodalcibep
—Not posted · NCT04790513

Lp(a), % change

Ebronucimab
—Not posted · NCT05260411
Lerodalcibep
—Not posted · NCT04790513

3-point MACE (% with event)

Ebronucimab
—Not posted · NCT05260411
Lerodalcibep
—Not posted · NCT04790513
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. Ebronucimab: 1 of 5 rows · Lerodalcibep: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricEbronucimabLerodalcibep
LDL-C
percent change · % of baseline
No placebo or comparator arm
-59.13% @ 12wk450 mg Q4Wa,b,c
NCT05255094 · Phase 3 · sponsor-reported, not registry data
show 1 more dose
-60.43% @ 12wk150 mg Q2W
NCT05255094 · Phase 3 · sponsor-reported, not registry data
58.61% @ 24wka,b,c
NCT04797104 · Phase 3 · sponsor-reported, not registry data
show 1 more dose
65%
NCT04797104 · Phase 3 · sponsor-reported, not registry data
Dropout rate—
18.8%d
NCT03847974 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs—
3.1%d
NCT03847974 · Phase 2 · registry result, not featured evidence
Serious AEs—
9.4%d
NCT03847974 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs—
d
other adverse event 87.5%
other (not including serious) adverse events were not monitored/assessed using specific adverse even 9.4%
NCT03847974 · Phase 2 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Lerodalcibep

LDL-C 64.1% (n=32) @ 52wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
NCT03847974 · Phase 2 · registry result, not featured evidence
LDL-C -53% vs -45.3% inclisiran @ 38.5714285714wk
percent change · % of baseline
NCT05004675 · Phase 3 · sponsor-reported, not registry data
show 1 more result
-9.26% vs -11% evolocumab @ 24wk
NCT04034485 · Phase 3 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ebronucimab's landscape · Lerodalcibep's landscape